{"result": "(\"entity\"<|>COLLABORATIVE EUROPEAN STUDY ON GLYCOGEN STORAGE DISEASE I<|>ORGANIZATION<|>The Collaborative European Study on Glycogen Storage Disease I is a research initiative focused on the treatment and management of Glycogen Storage Disease Type I, providing guidelines for nutritional objectives and recommendations for patients.)\n##\n(\"entity\"<|>GLYCOGEN STORAGE DISEASE I<|>EVENT<|>Glycogen Storage Disease Type I is a metabolic disorder that affects the body's ability to store and use glycogen, leading to various health complications, particularly in infants and children.)\n##\n(\"entity\"<|>DIAZOXIDE<|>ORGANIZATION<|>Diazoxide is a medication used to inhibit endogenous insulin production in patients who cannot maintain adequate blood glucose levels through nutritional treatment.)\n##\n(\"entity\"<|>ALMIDÓN DE MAÍZ<|>ORGANIZATION<|>Almidón de maíz is a type of carbohydrate recommended for patients with Glycogen Storage Disease I to help maintain normal blood glucose levels, especially before sleep.)\n##\n(\"entity\"<|>GLUCEMIA<|>EVENT<|>Glucemia refers to the levels of glucose in the blood, which are critical to monitor in patients with Glycogen Storage Disease I to prevent hypoglycemia and manage treatment.)\n##\n(\"entity\"<|>NUTRICIÓN ADECUADA<|>EVENT<|>Adequate nutrition is essential for patients with Glycogen Storage Disease I to ensure proper growth and development, involving specific dietary recommendations.)\n##\n(\"relationship\"<|>COLLABORATIVE EUROPEAN STUDY ON GLYCOGEN STORAGE DISEASE I<|>GLYCOGEN STORAGE DISEASE I<|>The Collaborative European Study provides guidelines and objectives for the treatment of Glycogen Storage Disease I<|>8)\n##\n(\"relationship\"<|>GLYCOGEN STORAGE DISEASE I<|>NUTRICIÓN ADECUADA<|>Adequate nutrition is a key component in managing Glycogen Storage Disease I<|>9)\n##\n(\"relationship\"<|>ALMIDÓN DE MAÍZ<|>GLUCEMIA<|>Almidón de maíz is used to help maintain normal glucemia levels in patients with Glycogen Storage Disease I<|>8)\n##\n(\"relationship\"<|>DIAZOXIDE<|>GLUCEMIA<|>Diazoxide is used to manage glucemia levels in patients who cannot achieve adequate levels through diet alone<|>7)\n##\n(\"relationship\"<|>GLYCOGEN STORAGE DISEASE I<|>DIAZOXIDE<|>Diazoxide is a treatment option for patients with Glycogen Storage Disease I when nutritional management is insufficient<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ia coriónica. Actualmente no es posible el diagnóstico bioquímico mediante determinación de los niveles de actividad enzimática debido a la poca precisión y al riesgo asociado a la biopsia hepática fetal.\n\n### 1.2.2. Objetivos nutricionales\n\nEl objetivo del tratamiento consiste en mantener unos niveles de glucemia normales y proporcionar una nutrición adecuada para conseguir un crecimiento y desarrollo adecuados. Muchas de las otras manifestaciones clínicas y parámetros bioquímicos como la acidosis láctica y la hipertrigliceridemia mejoran de forma paralela a la normalización de las glucemias.\n\nPara ello los pacientes deben evitar los períodos de ayuno mediante pequeñas ingestas frecuentes (cada 2-4 horas) durante el día de alimentos ricos en HC complejos y además almidón crudo de maíz entre comidas, así como soporte nocturno también con carbohidratos mediante perfusión enteral continua o tomas de almidón crudo de maíz. En un reciente metaanálisis que comparaba la nutrición enteral nocturna continua con el almidón crudo de maíz, se concluyó que los pacientes tratados con almidón de maíz mantenían glu-\n---\nTema 14. Soporte nutricional en patologías con alteración en el procesamiento... 215\n\ncemias más elevadas, sin embargo los niveles de lacta-\nto y colesterol eran mayores y no existieron diferencias\nen los niveles de triglicéridos.\n\nDurante la infancia el tratamiento debe ser intensivo,\nya que las hipoglucemias son más graves y frecuentes.\nA medida que pasan los años, los requerimientos de\nglucosa son menores y se puede flexibilizar el aporte de\nHC al finalizar el crecimiento y desarrollo. Llegados a\neste punto, muchos pacientes mantienen los niveles de\nglucemia solo con la toma de almidón de maíz antes\nde dormir. La monitorización de la glucemia capilar\npuede ayudar a ajustar el aporte de HC a las necesida-\ndes de cada individuo, evitando así las hipoglucemias y\nel sobretratamiento y sobrepeso.\n\nEn la tabla 1 se detallan los objetivos de tratamiento\nsegún las guías publicadas por la Collaborative Euro-\npean Study on Glycogen Storage Disease I.\n\nEn los pacientes en los que no se consigan unos nive-\nles adecuados de glucemia mediante tratamiento nutri-\ncional puede emplearse diazóxido a dosis bajas (3-5 mg/\nkg/día), que inhibe la producción endógena de insulina.\n\n### 1.2.3. Recomendaciones dietéticas\n\nTradicionalmente se consideraba que estos pacientes\ntenían unos requerimientos energéticos un 20-25% por\nencima del estimado para edad, peso y talla, basándose\nen estudios previos que calculaban la producción endó-\ngena de glucosa en individuos sanos. Sin embargo, tra-\nbajos recientes demuestran que esta producción endóge-\nna en personas sanas es un 20-25% menor de lo\ncalculado, y además se ha constatado que los pacientes\ncon GSDI tienen cierta actividad residual Glu6Pasa que\ncontribuye a dicha producción. Por lo tanto existe un cla-\nro riesgo de sobretratamiento y obesidad, así que el ma-\nnejo dietético debe tener un equilibrio que evite dicho\nexceso y también las manifestaciones clínicas de la enfer-\nmedad, especialmente en los lactantes y niños pequeños.\n\nSe recomienda un mayor aporte proporcional de HC,\nde tal forma que el reparto de macronutrientes respec-\n\nto al valor calórico total sería: HC = 60-70%, proteínas\n= 10-15%, lípidos = 10-15%.\n\n- Hidratos de carbono. Deben ser mayoritaria-\nmente HC complejos en forma de almidón, prefe-\nrentemente de arroz, maíz, patata y pan integral\npara niños y adolescentes, y almidón de arroz\npara lactantes. En el proceso de gluconeogénesis\nse precisa en última instancia de la actividad Glu-\n6Pasa, por lo que cualquier alimento que conten-\nga HC simples diferentes a la glucosa o que no se\nhidrolicen exclusivamente en este monosacárido\nno serán eficaces para mantener los niveles de\nglucemia. Además, el exceso de fructosa puede\ndesviarse a través del ciclo de Krebs hacia la ruta\ndel ácido láctico empeorando aún más la acidosis.\nPor este motivo debe evitarse, al menos en la in-\nfancia, el azúcar (sacarosa), las frutas y zumos\n(fructosa), el sorbitol o el jarabe de maíz rico en\nfructosa. De igual modo, la ingesta de lactosa y\ngalactosa debe limitarse en niños mayores a un\nvaso de leche desnatada, un yogur o unos 40 g de\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}